Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma | BMC Cancer | Full Text

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma | BMC Cancer | Full Text

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma

Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of a...

Authors:Rami Mäkelä, Antti Arjonen, Ville Härmä, Nina Rintanen, Lauri Paasonen, Tobias Paprotka, Kerstin Rönsch, Teijo Kuopio, Juha Kononen and Juha K. Rantala

Citation:BMC Cancer 2020 20:590

Content type:Research article

 

Published on: 23 June 2020

• ViewFull Text
 
• ViewPDF